Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Inclusion Criteria

* INCLUSION CRITERIA: * Age \>= 18 years. * Participants must be enrolled in an active treatment protocol at NIH utilizing cellular therapy, cellular engagers, or other novel monotherapy or combination immunotherapy agents associated with a known or anticipated risk profile for grade \>= 3 cytokine release syndrome (CRS) adverse effects. * Participants must be receiving immunotherapy dose(s) and be admitted to the Clinical Center. Note: Enrollment during the first week of treatment on an active treatment protocol, when CRS risk is highest, is preferable, but starting later during their active treatment course is acceptable. * Ability of the participant to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: * Prior solid organ or stem cell transplantation on active immunosuppression. * Regimen including antibiotics, for documented active infection within 7 days prior to study enrollment. * Current syndrome associated with cyclic fevers. * History of severe drug allergies, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). * Known current alcohol use disorder or drug use disorder that, in the opinion of the investigator, would interfere with the participant s ability to comply with study procedures or safely participate in the study.